ClinicalTrials.gov record
Completed Phase 2 Interventional

Trial of ARI-3037MO to Reduce Triglyceride Levels in Adults With Severe (≥500 mg/dl) Hypertriglyceridemia

ClinicalTrials.gov ID: NCT02250105

Public ClinicalTrials.gov record NCT02250105. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 17, 2026, 1:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Study identification

NCT ID
NCT02250105
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Arisaph Pharmaceuticals Inc
Industry
Enrollment
80 participants

Conditions and interventions

Interventions

  • ARI-3037MO Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 2014
Primary completion
May 31, 2016
Completion
May 31, 2016
Last update posted
Aug 7, 2016

2014 – 2016

United States locations

U.S. sites
5
U.S. states
5
U.S. cities
5
Facility City State ZIP Site status
Orange County Research Center Tustin California 92780
Louisville Metabolic and Atherosclerosis Research Center Louisville Kentucky 40213
Maine Research Associates Auburn Maine 04210
Sterling Clinical Research Inc Cincinnati Ohio 45219
National Clinical Research inc Richmond Virginia 23294

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02250105, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 7, 2016 · Synced May 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02250105 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →